title: IXIARO updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis.
abstract: The mosquito-borne Japanese encephalitis virus causes an estimated 50,000 cases in Asia, accounting for at least 10,000 deaths and 15,000 cases of neuropsychiatric sequelae. IXIARO (Intercell AG, Vienna, Austria), an inactivated, Vero cell-derived vaccine against Japanese encephalitis was introduced in 2009. The vaccine is highly immunogenic, showing significantly higher geometric mean antibody titers compared with previous, mouse brain-derived vaccines. Postmarketing studies have confirmed the excellent safety profile. Studies on children aged 2 months to 18 years have been published. Based on these data, positive opinion from the EMA for vaccination of children has recently been given. Since a safe and effective vaccine against Japanese encephalitis is now available, outdated guidelines and recommendations have to be revised: travelers to rural areas of Asia should generally be recommended vaccination.
authors.affiliation: Berlin Center for Travel and Tropical Medicine, Jägerstrasse 67-69, 10117 Berlin, Germany. jelinek@bctropen.de.
authors.forename: Tomas
authors.initials: T
authors.lastname: Jelinek
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D001208:Asia; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D004672:Encephalitis, Japanese / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D022321:Japanese Encephalitis Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011358:Product Surveillance, Postmarketing; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines; D015164:Vaccines, Inactivated